Alemtuzumab: neurological complications
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Alemtuzumab: neurological complications. Disseminated necrotising leukoencephalitis. Fully referenced neurology checklist.
Neuroinflammatory
- Disseminated necrotising leukoencephalitis
- Exacerbation of neuroinflammation
- Progressive multifocal leukoencephalopathy (PML)
Vascular
Locked: subscribe to see this section.
Neuromuscular
Locked: subscribe to see this section.
References
- Metz I, Rieckmann P, Kallmann BA, Brück W. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis. Acta Neuropathol Commun 2016; 4:81.
- Haghikia A, Dendrou CA, Schneider R, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol 2017; 16:104-106.
- Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2019; 25:1196-1201.
- Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol 2019; 18:329-331.
- FDA Drug Safety Communication. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). FDA website accessed 28 June 2019.
- And 7 more. Subscribe to see the full list
